JavaScript is disabled for your browser. Some features of this site may not work without it.
Mostrar el registro sencillo del objeto digital
| dc.contributor.author | ESCUDERO CASTELLANOS, ALONDRA
|
es |
| dc.contributor.author | OCAMPO GARCIA, BLANCA ELI
|
es |
| dc.contributor.author | FERRO FLORES, GUILLERMINA
|
es |
| dc.contributor.author | ISAAC OLIVE, KEILA
|
es |
| dc.contributor.author | SANTOS CUEVAS, CLARA LETICIA
|
es |
| dc.contributor.author | OLMOS ORTIZ, ANDREA GUADALUPE
|
es |
| dc.contributor.author | GARCIA QUIROZ, JANICE
|
es |
| dc.contributor.author | GARCIA BECERRA, ROCIO ANGELES
|
es |
| dc.contributor.author | DIAZ NIETO, LORENZA
|
es |
| dc.creator | ESCUDERO CASTELLANOS, ALONDRA; 634726 | |
| dc.creator | OCAMPO GARCIA, BLANCA ELI; 309879 | |
| dc.creator | FERRO FLORES, GUILLERMINA; 19581 | |
| dc.creator | ISAAC OLIVE, KEILA; 243975 | |
| dc.creator | SANTOS CUEVAS, CLARA LETICIA; 171596 | |
| dc.creator | OLMOS ORTIZ, ANDREA GUADALUPE; 326192 | |
| dc.creator | GARCIA QUIROZ, JANICE; 253721 | |
| dc.creator | GARCIA BECERRA, ROCIO ANGELES; 36851 | |
| dc.creator | DIAZ NIETO, LORENZA; 21753 | |
| dc.date.accessioned | 2018-03-08T04:56:09Z | |
| dc.date.available | 2018-03-08T04:56:09Z | |
| dc.date.issued | 2017-10-20 | |
| dc.identifier.issn | 0236-5731 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.11799/79748 | |
| dc.description.abstract | This study aimed to synthesize a new 177Lu-iPSMA-RGD heterobivalent radiopharmaceutical, as well as to assess the in vitro radiopharmaceutical potential to target cancer cells overexpressing PSMA and a(v) b(3) integrins. The radiotracer prepared with a radiochemical purity of 98.8 ± 1.0% showed stability in human serum, specific recognition with suitable affinity to PSMA and a(v)b(3) integrins, and capability to inhibit cancer cell proliferation and VEGF signaling (antiangiogenic effect). Results warrant further preclinical studies to establish the 177Lu-iPSMA-RGD potential as a dual therapeutic radiopharmaceutical. | es |
| dc.description.sponsorship | CONACyT-CB-2016-01-281526 | es |
| dc.language.iso | eng | es |
| dc.publisher | J Radioanal Nucl Chem | es |
| dc.relation.ispartofseries | DOI 10.1007/s10967-017-5555-9; | |
| dc.rights | openAccess | es |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0 | |
| dc.subject | PSMA inhibitor | es |
| dc.subject | RGD peptide | es |
| dc.subject | 177Lu | es |
| dc.subject | 177Lulabeled PSMA inhibitor | es |
| dc.subject | 177Lu-labeled RGD | es |
| dc.subject | Heterobivalent radiopharmaceutical | es |
| dc.subject.classification | MEDICINA Y CIENCIAS DE LA SALUD | |
| dc.title | Preparation and in vitro evaluation of 177Lu-iPSMA-RGD as a new heterobivalent radiopharmaceutical | es |
| dc.type | Artículo | es |
| dc.provenance | Científica | es |
| dc.road | Dorada | es |
| dc.organismo | Medicina | es |
| dc.ambito | Internacional | es |
| dc.cve.progEstudios | 746 | es |
| dc.audience | students | |
| dc.audience | researchers | |
| dc.type.conacyt | article | |
| dc.identificator | 3 |
Ficheros en el objeto digital
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Conacyt [10019]
-
Científica [1177]
Visualización del Documento
- Los documentos depositados en el Repositorio Institucional de la Universidad Autónoma del Estado de México se encuentran a disposición en Acceso Abierto bajo la licencia Creative Commons: Atribución-NoComercial-SinDerivar 4.0 Internacional (CC BY-NC-ND 4.0)
Excepto si se señala otra cosa, la licencia del ítem se describe cómo openAccess